Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06739317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06739317 · ClinicalTrials.gov record · last posted 2024-12-18

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Name: SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. — clinical trial record (NCT06739317)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorSun Yat-sen University

Started2025-01-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.

Trial Details

NCT Number	NCT06739317
Lead Sponsor	Sun Yat-sen University
Conditions	Unresectable Hepatocellular Carcinoma (HCC)
Enrollment	398 participants
Start Date	2025-01-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2031-06-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-18